Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C15H14N2O2 |
| Molecular Weight | 254.2844 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
c1ccc2c(c1)CC(c3ccccc3N2C(=N)O)O
InChI
InChIKey=BMPDWHIDQYTSHX-UHFFFAOYSA-N
InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)
| Molecular Formula | C15H14N2O2 |
| Molecular Weight | 254.2844 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Licarbazepine is the pharmacologically active metabolite of oxcarbazepine, a drug indicated for the treatment of partial seizures and bipolar disorders. Phase III trials of licarbazepine were conducted in the US and Europe, and were initially delayed in November 2006. An isomer of licarbazepine, eslicarbazepine ((S)-(+)-licarbazepine), is an active metabolite of eslicarbazepine acetate.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Suppressive effects of oxcarbazepine on tooth pulp-evoked potentials recorded at the trigeminal spinal tract nucleus in cats. | 2001 Mar |
|
| Oxcarbazepine final market image tablet formulation bioequivalence study after single administration and at steady state in healthy subjects. | 2002 Nov |
|
| Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects. | 2003 Jul |
|
| Overview of the clinical pharmacokinetics of oxcarbazepine. | 2004 |
|
| Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. | 2004 Aug |
|
| Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy. | 2005 Dec 15 |
|
| A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. | 2005 Oct |
|
| Drug monitoring and toxicology: a procedure for the monitoring of oxcarbazepine metabolite by HPLC-UV. | 2006 Jan |
|
| Simultaneous and enantioselective liquid chromatographic determination of eslicarbazepine acetate, S-licarbazepine, R-licarbazepine and oxcarbazepine in mouse tissue samples using ultraviolet detection. | 2007 Jul 16 |
|
| A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in human plasma. | 2007 Jun |
|
| Stereoselective disposition of S- and R-licarbazepine in mice. | 2008 Jun |
|
| Pharmacokinetics of licarbazepine in healthy volunteers: single and multiple oral doses and effect of food. | 2008 May |
|
| Eyeblink conditioning anomalies in bipolar disorder suggest cerebellar dysfunction. | 2009 Feb |
|
| Binding of licarbazepine enantiomers to mouse and human plasma proteins. | 2010 Jul |
|
| Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma. | 2010 Jun |
Patents
Sample Use Guides
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 15:35:18 UTC 2021
by
admin
on
Sat Jun 26 15:35:18 UTC 2021
|
| Record UNII |
XFX1A5KJ3V
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C264
Created by
admin on Sat Jun 26 15:35:19 UTC 2021 , Edited by admin on Sat Jun 26 15:35:19 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7788
Created by
admin on Sat Jun 26 15:35:19 UTC 2021 , Edited by admin on Sat Jun 26 15:35:19 UTC 2021
|
PRIMARY | |||
|
29331-92-8
Created by
admin on Sat Jun 26 15:35:19 UTC 2021 , Edited by admin on Sat Jun 26 15:35:19 UTC 2021
|
PRIMARY | |||
|
C81475
Created by
admin on Sat Jun 26 15:35:19 UTC 2021 , Edited by admin on Sat Jun 26 15:35:19 UTC 2021
|
PRIMARY | |||
|
CHEMBL1067
Created by
admin on Sat Jun 26 15:35:19 UTC 2021 , Edited by admin on Sat Jun 26 15:35:19 UTC 2021
|
PRIMARY | |||
|
SUB32907
Created by
admin on Sat Jun 26 15:35:19 UTC 2021 , Edited by admin on Sat Jun 26 15:35:19 UTC 2021
|
PRIMARY | |||
|
XFX1A5KJ3V
Created by
admin on Sat Jun 26 15:35:19 UTC 2021 , Edited by admin on Sat Jun 26 15:35:19 UTC 2021
|
PRIMARY | |||
|
114709
Created by
admin on Sat Jun 26 15:35:19 UTC 2021 , Edited by admin on Sat Jun 26 15:35:19 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
BINDER->LIGAND |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> METABOLITE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
